AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3034538 — intervention group
Group type: COMPARATOR
Intervention: Intravenous control group
Number of subjects: 82
Study 29280011 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 99
Study 29280011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 26667118 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach based on atraumatic restorative treatment (ART) procedures
Number of subjects: 254
Study 26667118 — intervention group
Group type: COMPARATOR
Intervention: Standard-care approach
Number of subjects: 254
Study 22559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 474
Study 22559255 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 474
Study 20415692 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLA)
Number of subjects: 28
Study 20415692 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 28
Study 18093252 — intervention group
Group type: EXPERIMENTAL
Intervention: Coracten (encapsulated mini-tablet)
Number of subjects: 44
Study 18093252 — intervention group
Group type: EXPERIMENTAL
Intervention: N-GITS (30-mg osmotic, constant-release nifedipine gastrointestinal therapeutic system)
Number of subjects: 44
Study 18093252 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Coracten and N-GITS
Number of subjects: 44
Study 15978926 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 338
Study 15978926 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 338
Study 12201975 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium symptoms post-surgery
Number of subjects: 52
Study 12201975 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-delirious patients)
Number of subjects: 52
Study 10475139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg oral budesonide
Number of subjects: 24
Study 10475139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8757005 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 266
Study 8757005 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg)
Number of subjects: 266
Study 1761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation alone
Number of subjects: 444
Study 1761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with IUI
Number of subjects: 444
Study 1761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with IPI
Number of subjects: 444
Study 1761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with GIFT
Number of subjects: 444
Study 1761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with IVF
Number of subjects: 444
Study 7106687 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebodril (fixed combination)
Number of subjects: 20
Study 7106687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylhesperidinchalcone
Number of subjects: 20
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean dietary score
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s chair stand test
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate vitamin C consumption
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte count
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils and monocytes
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio
Number of subjects: 1535
Study 31144432 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 1535
Study 26858430 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-h inverted behavioral and environmental cycles for three days)
Number of subjects: 0
Study 26858430 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study 24982780 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 60 mg/day and Solifenacin 20 mg/day during two cycles (1.5 and 1 month with one month interval)
Number of subjects: 313
Study 24982780 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 60 mg/day and Solifenacin 20 mg/day during one cycle therapy
Number of subjects: 313
Study 24982780 — intervention group
Group type: COMPARATOR
Intervention: Placebo during second cycle
Number of subjects: 313
Study 24982780 — intervention group
Group type: COMPARATOR
Intervention: Control groups (A3, B3)
Number of subjects: 313
Study 22367125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellet stove condition
Number of subjects: 16
Study 22367125 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 16
Study 19920098 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus/prostate-specific antigen (PSA) vaccine
Number of subjects: 32
Study 17214953 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent verbal protocol method
Number of subjects: 18
Study 17214953 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective verbal protocol method
Number of subjects: 18
Study 17214953 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 18
Study 17214953 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of concurrent reports
Number of subjects: 18
Study 15201372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue acupuncture (TAC), n = 22
Number of subjects: 33
Study 15201372 — intervention group
Group type: COMPARATOR
Intervention: Control (sham acupuncture), n = 11
Number of subjects: 33
Study 11695210 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 83
Study 11695210 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 83
Study 9794929 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus Interferon (CIFN) 9 microgram for 6 months
Number of subjects: 232
Study 9794929 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with Consensus Interferon (CIFN) 15 microgram
Number of subjects: 232
Study 7658483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g calcium
Number of subjects: 193
Study 7658483 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g calcium
Number of subjects: 193
Study 7658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium groups
Number of subjects: 193
Study 7658483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 2520621 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 138
Study 2520621 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine q.d.s.
Number of subjects: 138
Study 843418 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 843418 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 30429592 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 session home‐based CBT (minimal contact (MC‐CBT))
Number of subjects: 436
Study 30429592 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 session clinic‐based CBT (standard (S‐CBT))
Number of subjects: 436
Study 30429592 — intervention group
Group type: COMPARATOR
Intervention: 4 session IBS education (EDU)
Number of subjects: 436
Study 27815631 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-tube-assisted endoscopic septoplasty (Group 2)
Number of subjects: 434
Study 27815631 — intervention group
Group type: COMPARATOR
Intervention: Traditional septoplasty (Group 1)
Number of subjects: 434
Study 26416025 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based exercise training (IBET)
Number of subjects: 350
Study 26416025 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy (PT)
Number of subjects: 350
Study 26416025 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL) control group
Number of subjects: 350
Study 23560480 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise (VRE) program
Number of subjects: 55
Study 23560480 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - diabetes education only
Number of subjects: 55
Study 21864622 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5-mcg or 30-mcg of hemagglutinin intramuscularly
Number of subjects: 121
Study 21864622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study 19644190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercamen (lercadipine) 10-20 mg
Number of subjects: 80
Study 19644190 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 80
Study 17905575 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg two inhalations twice daily and as needed
Number of subjects: 2309
Study 17905575 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 microg one inhalation twice daily plus terbutaline as needed
Number of subjects: 2309
Study 15388510 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg at week 0, 2, and 6)
Number of subjects: 30
Study 15388510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12196773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasobiliary catheter (NBC group)
Number of subjects: 79
Study 12196773 — intervention group
Group type: COMPARATOR
Intervention: Indwelling stent (stent group)
Number of subjects: 79
Study 9787699 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron weaning diet (8.2 +/‐ 2.9 mg/day)
Number of subjects: 62
Study 9787699 — intervention group
Group type: COMPARATOR
Intervention: Control group weaning diet (5.2 +/‐ 3.4 mg/day)
Number of subjects: 62
Study 8925517 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly wine consumption
Number of subjects: 177
Study 8925517 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional consumption of spirits
Number of subjects: 177
Study 8925517 — intervention group
Group type: COMPARATOR
Intervention: Abstaining from alcohol
Number of subjects: 177
Study 8925517 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 177
Study 8925517 — intervention group
Group type: COMPARATOR
Intervention: Beer consumption
Number of subjects: 177
Study 2673511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (15 mg) followed by oral metoprolol (200 mg daily for 15 days)
Number of subjects: 69
Study 2673511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31096478 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-stent kissing technique (BSKT)
Number of subjects: 89
Study 31096478 — intervention group
Group type: COMPARATOR
Intervention: Jailed wire technique (JWT)
Number of subjects: 89
Study 28558732 — intervention group
Group type: EXPERIMENTAL
Intervention: B. infantis supplementation (BiLS)
Number of subjects: 80
Study 28558732 — intervention group
Group type: COMPARATOR
Intervention: Lactation support alone (LS)
Number of subjects: 80
Study 25417843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivia Game (treatment group)
Number of subjects: 27
Study 25417843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 23325671 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time elastography-guided biopsy
Number of subjects: 231
Study 23325671 — intervention group
Group type: COMPARATOR
Intervention: Grey-scale ultrasound-guided biopsy
Number of subjects: 231
Study 22047559 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inhibitor coagulant complex (AICC) prophylaxis at a target dose of 85 U/kg (±15%) on 3 nonconsecutive days per week
Number of subjects: 34
Study 22047559 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy (AICC at a target dose of 85 U/kg [±15%] used for bleeding episodes)
Number of subjects: 34
Study 19925045 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 25620
Study 19925045 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 25620
Study 19925045 — intervention group
Group type: COMPARATOR
Intervention: Combination of Ramipril and Telmisartan
Number of subjects: 25620
Study 19780298 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cisplatin-based intraperitoneal therapy
Number of subjects: 0
Study 19780298 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin-based treatment
Number of subjects: 0
Study 10400014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate (1 g IV) after bradykinin infusion into the iliac artery
Number of subjects: 18
Study 10400014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate (1 g IV) after bradykinin infusion into the left coronary artery
Number of subjects: 18
Study 8531622 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 44
Study 8531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (D)
Number of subjects: 44
Study 8531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + cycling (DC)
Number of subjects: 44
Study 8531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + resistance training (DR)
Number of subjects: 44
Study 8531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + resistance training + cycling (DRC)
Number of subjects: 44
Study 2100324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg i.v.
Number of subjects: 48
Study 2100324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg i.v. and metoclopramide, 10 mg i.v.
Number of subjects: 48
Study 2100324 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control group)
Number of subjects: 48
Study 7369098 — intervention group
Group type: EXPERIMENTAL
Intervention: Prajmalium bitartrate (60 mg orally, 20 mg every 4 hours)
Number of subjects: 35
Study 7369098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2.1 mg/minute infusion, daily dose of 3 g)
Number of subjects: 35
Study 7369098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic drug)
Number of subjects: 35
Study 30675865 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice stimulation (listened to mothers' voice from 1 minute before heel blood collection to the end of the procedure)
Number of subjects: 72
Study 30675865 — intervention group
Group type: COMPARATOR
Intervention: Routine method of heel blood collection (control group)
Number of subjects: 72
Study 28202358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipotoxin (onabotulinumtoxinA 200 U with 80 mg sphingomyelin)
Number of subjects: 90
Study 28202358 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA in normal saline (200 U)
Number of subjects: 90
Study 28202358 — intervention group
Group type: COMPARATOR
Intervention: Normal saline alone
Number of subjects: 90
Study 26164310 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink blink animation
Number of subjects: 34
Study 26164310 — intervention group
Group type: COMPARATOR
Intervention: Placebo version
Number of subjects: 34
Study 23830534 — intervention group
Group type: EXPERIMENTAL
Intervention: Information regarding herpes zoster vaccination via electronic message (for personal health record users)
Number of subjects: 2589
Study 23830534 — intervention group
Group type: EXPERIMENTAL
Intervention: Information regarding herpes zoster vaccination via US Postal Service (for nonpersonal health record users)
Number of subjects: 2589
Study 23830534 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group for both personal and nonpersonal health record users)
Number of subjects: 2589
Study 22131602 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based evaluation and treatment of OSA
Number of subjects: 135
Study 22131602 — intervention group
Group type: COMPARATOR
Intervention: Lab-based evaluation and treatment of OSA
Number of subjects: 135
Study 19523047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 19523047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 17726365 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 1428
Study 17726365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1428
Study 15203781 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent ALL (C‐ALL)
Number of subjects: 40
Study 15203781 — intervention group
Group type: COMPARATOR
Intervention: Contingent LAST (C‐LAST)
Number of subjects: 40
Study 11380324 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg)
Number of subjects: 33
Study 11380324 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (125 microg)
Number of subjects: 33
Study 9564987 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol/nedocromil combination (200 microg/4 mg)
Number of subjects: 12
Study 9564987 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol alone (200 microg)
Number of subjects: 12
Study 9564987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 12
Study 7981487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 7981487 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0
Study 7981487 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin
Number of subjects: 0
Study 7981487 — intervention group
Group type: EXPERIMENTAL
Intervention: JM216
Number of subjects: 0
Study 7981487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Tetraplatin
Number of subjects: 0
Study 30265816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25 µg
Number of subjects: 61
Study 30265816 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/Formoterol (BUD/FOR) 400 µg/12 µg
Number of subjects: 61
Study 30265816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Number of subjects: 61
Study 30265816 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/Formoterol (BUD/FOR)
Number of subjects: 61
Study 27424935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer or calcium acetate, calcitriol, and changes in calcium dialysate concentration
Number of subjects: 52
Study 27424935 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 52
Study 24841018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pre-operative antibiotics
Number of subjects: 251
Study 24841018 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 251
Study 23797006 — intervention group
Group type: COMPARATOR
Intervention: 20 mg chitosan gum twice daily for 4 weeks in ESRD
Number of subjects: 0
Study 23797006 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg chitosan gum three times daily in open-label extension in ESRD
Number of subjects: 0
Study 23797006 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg chitosan gum three times daily for 2 weeks in CKD not on dialysis
Number of subjects: 0
Study 20207251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with povidone iodine
Number of subjects: 300
Study 20207251 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no vaginal wash)
Number of subjects: 300
Study 19249433 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with the Export catheter (n = 20)
Number of subjects: 44
Study 19249433 — intervention group
Group type: COMPARATOR
Intervention: PCI-only group (n = 24)
Number of subjects: 44
Study 16765187 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 56
Study 16765187 — intervention group
Group type: COMPARATOR
Intervention: High-ligation surgery
Number of subjects: 56
Study 14992738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin raffimer (HR)
Number of subjects: 299
Study 14992738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch
Number of subjects: 299
Study 14992738 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (reference group)
Number of subjects: 299
Study 11726473 — intervention group
Group type: COMPARATOR
Intervention: Tug of war athletes
Number of subjects: 16
Study 9000193 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose polyagent self‐administered intracavernous pharmacotherapy
Number of subjects: 188
Study 9000193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose polyagent self‐administered intracavernous pharmacotherapy
Number of subjects: 188
Study 9000193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum constriction device (VCD)
Number of subjects: 188
Study 7956623 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 83
Study 7956623 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with apoA-IV-1-2 phenotype
Number of subjects: 83
Study 3583493 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) 25 nmol/kg
Number of subjects: 0
Study 3583493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29133566 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg iclaprim administered as a 2-h infusion every 12 h
Number of subjects: 470
Study 29133566 — intervention group
Group type: COMPARATOR
Intervention: 0.8 mg/kg iclaprim infused intravenously over 0.5 h every 12 h (previous regimen)
Number of subjects: 470
Study 27154868 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapatellar approach group (SPAG)
Number of subjects: 162
Study 27154868 — intervention group
Group type: COMPARATOR
Intervention: Infrapatellar approach group (IPAG)
Number of subjects: 162
Study 24080948 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic test battery (including automatic pure-tone air conduction audiometry and tone-in-noise detection task)
Number of subjects: 120